Yderligere analyser af undergrupper viste en høj risiko for progression til CDMS inden for 2 år hos monofokale patienter med mindst 9 T2- læsioner (55% risiko for placebo, 26% for Betaferon) eller Gd- forstærkning (63% mod 33%).
Further subgroup analyses indicated a high risk for progression to CDMS within 2 years in monofocal patients with at least 9 T2- lesions (55% risk for placebo, 26% for Betaferon) or Gd-enhancement (63% versus 33%).